Accelerating IND ‐enabling toxicology studies using protein products from stable pools or pools of clones in Chinese hamster ovary cells
Biotechnology Progress · 2025
DOI: 10.1002/btpr.70040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, 2025. Verfasst von Yiwen Jiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: WuXi Biologics, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
In recent years, accelerating Chemistry, Manufacturing, and Controls (CMC) workflows for clinical entry has become a critical focus in biologics development. Advances in the development of cell lines, cell culture processes, and analytical technologies have enabled the generation of more homogeneous stable pool populations with increased productivity. Leveraging the experience gained from the COVID‐19 product development, the strategic use of stable cell pools or a pool of clones for early‐stage non‐GMP material generation and process development has proven transformative in significantly reducing the CMC timeline to investigational new drug (IND). This study provides a comprehensive comparison of bioprocess performance and product quality attributes of materials produced from stable pools or a pool of clones (toxicology study materials) versus those from clonally derived cells (GMP clinical batches) across six First‐in‐Human (FIH) programs involving mAbs, bsAb, and Fc‐fusion proteins. The results demonstrate a strong alignment and the feasibility of using protein materials from stable pools or a pool of clones in toxicology studies. In conclusion, utilizing non‐clonal CHO cell‐derived material for preclinical studies offers a strategic approach that can be broadly applied to complex molecules across various disease areas, even under standard regulatory filings, accelerating the path to clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- WuXi Biologics, Shanghai, China.
- WuXi Biologics, Cranbury, New Jersey, USA.
ORCID-Profile: Ying Huang
Zitieren
APA
Jiang, Y., Jiang, L., Yang, Z., Liu, X., Wang, Y., Ying, M., Huang, H., Xu, Y., Zhou, H., Huang, J., Gu, X., Zhou, W., & Huang, Y. (2025). Accelerating IND ‐enabling toxicology studies using protein products from stable pools or pools of clones in Chinese hamster ovary cells. Biotechnology Progress. https://doi.org/10.1002/btpr.70040
Vancouver
Jiang Y, Jiang L, Yang Z, Liu X, Wang Y, Ying M, et al. Accelerating IND ‐enabling toxicology studies using protein products from stable pools or pools of clones in Chinese hamster ovary cells. Biotechnology Progress. 2025. doi:10.1002/btpr.70040
BibTeX
@article{Jiang2025,
author = {Jiang, Yiwen and Jiang, Lingxi and Yang, Zhongwei and Liu, Xiaolin and Wang, Yaoyao and Ying, Man and Huang, He and Xu, Yiren and Zhou, Hang and Huang, Jincui and Gu, Xuejun and Zhou, Weichang and Huang, Ying},
title = {Accelerating IND ‐enabling toxicology studies using protein products from stable pools or pools of clones in Chinese hamster ovary cells},
journal = {Biotechnology Progress},
year = {2025},
doi = {10.1002/btpr.70040}
}
EUVIMED